Over 295,000 VSDHOne product orders between July and September, accelerating nurse network growth and a strong balance sheet with approximately CA$18.7 million in cash; Hydreight continues to build the infrastructure for compliant, nationwide digital healthcare delivery. VANCOUVER, British Columbia and LAS VEGAS, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (“Hydreight” or the “Company”) (TSXV: NURS | OTCQB: HYDTF | FSE: SO6) today announced a corporate update, alongside a series of prestig ...

Over 295,000 VSDHOne product orders between July and September, accelerating nurse network growth and a strong balance sheet with approximately CA$18.7 million in cash; Hydreight continues to build the infrastructure for compliant, nationwide digital healthcare delivery. VANCOUVER, British Columbia and LAS VEGAS, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (“Hydreight” or the “Company”) (TSXV: NURS | OTCQB: HYDTF | FSE: SO6) today announced a corporate update, alongside a series of prestig ...

Core Insights - Hydreight Technologies Inc. has reported stronger-than-expected order growth and strategic advancements, indicating a robust performance in the mobile clinical network sector [1][2][3] Order Growth and Market Momentum - In August 2025, Hydreight processed over 80,000 pharmacy and telehealth product orders, exceeding the internal forecast of approximately 55,000 orders, reflecting broad demand across multiple service lines [2] - The company has seen an 86% year-over-year increase in pharmacy orders from January to August 2025, indicating significant market momentum [3] Strategic Growth Initiatives - Hydreight has invested in making the VSDHOne platform fully modular, enhancing customer adoption and expanding its total addressable market [4] - The company reported a 33% year-over-year revenue growth for H1 2025, marking its third consecutive quarter of profitability, driven by strong pharmacy order growth and network expansion [4] - An oversubscribed financing round raised $11.5 million to support strategic initiatives and strengthen the balance sheet [4] - The acquisition of a 5% stake in Perfect Scripts LLC aims to enhance operational control over pharmacy fulfillment and support margin expansion [4] AI Integration - Hydreight is in due diligence to acquire an AI-driven tool designed to provide personalized IV treatment recommendations, which is expected to enhance clinical decision-making and marketing capabilities [5] Customer Lifetime Value (LTV) Expansion - The company is focusing on expanding Customer Lifetime Value (LTV) by encouraging patients to engage with multiple service offerings within its ecosystem, thereby deepening patient relationships and improving unit economics [6] Outlook - Management emphasizes the need for continued investment in infrastructure, technology, and regulatory compliance to sustain growth, particularly in integrating new acquisitions [7] Competitive Position - Hydreight believes its established provider network, expanding pharmacy relationships, and growing patient demand position it favorably in the fragmented U.S. digital health market [8] Management Commentary - The CEO highlighted the broad-based adoption of Hydreight's services across various healthcare segments, indicating a strong platform performance [9] - The company is committed to building a scalable and compliant model that delivers value to patients, providers, and shareholders [10]

Core Viewpoint - Hydreight Technologies Inc. has entered into a strategic partnership with Perfect Scripts LLC, which includes acquiring a 5% membership interest in Perfect Scripts and establishing a 503B pharmacy in the U.S. [1][2] Company Overview - Hydreight Technologies Inc. operates a fully integrated mobile clinical network in North America, comprising over 2,500 nurses and 100 doctors, along with a pharmacy network across all 50 states [13][14]. - Perfect Scripts LLC is the parent company of PerfectRx LLC and PerfectionRx LLC, which operate pharmacies and provide pharmaceutical services [6][9]. Transaction Details - Hydreight will acquire a 5% membership interest in Perfect Scripts for 2,250,000 common shares, with a deemed price of CAD$2.30 per share or the lowest price permitted by the TSX Venture Exchange [2]. - The partnership will allow Hydreight to receive the lowest pricing for products sold by Perfect Scripts and grants the right to maintain and increase its membership interest up to 40% [2][3]. Financial Aspects - A cash finder's fee of $258,750 will be paid to a finder in connection with the transaction, representing 5% of the deemed value [3]. - The Hydreight Compensation Shares will vest in increments and are subject to a four-month statutory hold period under Canadian securities laws [4][5]. Strategic Implications - The partnership is expected to enhance Hydreight's pharmacy margins, secure a consistent supply chain, and provide vertical integration, which will strengthen its market position [6][8]. - The U.S. compounding pharmacy sector is projected to grow from $6.31 billion in 2024 to $10.76 billion by 2033, indicating significant market potential for Hydreight and Perfect Scripts [8]. Operational Capabilities - PerfectRx LLC operates a 30,000 sq ft licensed pharmacy and distribution center in Florida and can process over 150,000 prescriptions per day [7][10]. - The proprietary technology, PerfectOS, enables efficient digital prescription intake and real-time inventory management, enhancing operational efficiency [10][11]. Future Outlook - The partnership is viewed as a critical step in transforming access to modern healthcare and expanding Hydreight's product lineup [8]. - The VSDHOne platform, developed in partnership with Victory Square Technologies, aims to simplify the entry for companies into the online healthcare space, further supporting Hydreight's growth strategy [15].

Core Insights - Hydreight Technologies Inc. has reported record-breaking growth in orders for its VSDHOne platform, with July orders significantly exceeding projections and August tracking ahead of schedule towards a goal of 1.3 million total orders for 2025 [2][4] - The partnership with Perfect Scripts and the introduction of 503B compounding capabilities are expected to enhance the scalability, efficiency, and reach of the VSDHOne platform [4][7] - The launch of Hydreight Marketing Solutions aims to drive client growth and increase order volume across the VSDHOne network by providing marketing services tailored for healthcare providers [8][9] Order Growth - VSDHOne platform achieved approximately 7,187 SKU orders in June 2025, surpassing the internal forecast of 7,000–10,000 SKU orders [6] - In July 2025, the platform achieved approximately 35,642 SKU orders, over three times the internal forecast of around 10,000 SKU orders [6] - The internal forecast for August 2025 aims for approximately 55,000 SKU orders [6] Technology and Integration - Hydreight is enhancing the VSDHOne technology platform into a fully modular architecture, allowing businesses to adopt only the necessary components for order generation [3] - Perfect Scripts' technology integrates directly with VSDHOne, automating prescription processing and significantly reducing fulfillment times [7] - The 503B compounding capability allows Hydreight to manufacture and ship high-demand medications at scale, overcoming the limitations of traditional compounding methods [7] Marketing Solutions - Hydreight Marketing Solutions will provide data-driven campaigns and patient acquisition strategies specifically for healthcare providers on the VSDHOne platform [8] - The initiative is expected to drive significant growth, as successful marketing at the client level translates to higher patient volumes and order growth across the network [9] - The goal is to empower partners to market effectively, increasing patient engagement and revenue for all involved [9] Corporate Update - Gabi Kabazo has resigned as a director effective August 8, 2025, to focus on other professional commitments [10] - Hydreight Technologies Inc. has been recognized as the 56th fastest-growing company in North America on the 2024 Deloitte Technology Fast 500™ [11]

Core Insights - Hydreight Technologies Inc. is a rapidly growing digital health platform focused on transforming mobile and telehealth services in the U.S. [1] - The company will present at two investor conferences in June 2025, showcasing its healthcare infrastructure and technology platform [1][2] - Recent financial results indicate significant growth, with adjusted revenue increasing by 31% year-over-year [6] Financial Performance - FY2024 Adjusted Revenue reached $22.32 million CAD, a 31% increase year-over-year [6] - GAAP Revenue was reported at $16.04 million CAD, reflecting a 39% year-over-year growth [6] - Adjusted EBITDA improved to +$490,000 CAD, compared to a loss of -$1.38 million CAD in FY2023 [6] - Cash Flow from Operations was positive at +$857,000 CAD, with a current cash position of $6.8 million CAD [6] Business Expansion - In 2024, Hydreight expanded its service offerings to include Liraglutide, NAD+, TRT, peptide therapies, and oral weight-loss medications [4] - The company secured strategic partnerships with national health franchises and clinical experts, enhancing its service capabilities [4] - Hydreight has sold over 400 licenses to direct-to-consumer (D2C) brands across all 50 states, indicating strong market penetration [6] Technology and Platform Development - The VSDHOne platform was developed to facilitate compliant entry for companies into the online healthcare space, significantly reducing launch time and costs [9] - Hydreight's platform supports a network of over 3,000 nurses and 200 physicians, providing a comprehensive mobile clinic network across the U.S. [8] - The platform includes integrated tools for accounting, documentation, sales, inventory, and patient data management, enhancing operational efficiency for healthcare professionals [8]

Core Insights - Hydreight Technologies Inc. has reported significant growth in its financial performance for the fiscal year 2024, achieving record revenues and positive Adjusted EBITDA, while focusing on scaling its VSDHOne platform for 2025 [2][6][9]. Financial Performance - The company achieved record topline revenue of CAD 22.32 million in 2024, representing a 31% increase from 2023 [6][17]. - GAAP revenue for 2024 was CAD 16.04 million, up 39% from CAD 11.51 million in 2023 [6][9]. - Adjusted EBITDA for 2024 was CAD 490,000, a turnaround from a loss of CAD 1.38 million in 2023 [6][17]. - The gross margin for 2024 was CAD 5.75 million, an increase of 8% from the previous year [6][17]. - The fourth quarter of 2024 saw revenues of CAD 4.04 million, a 20% increase compared to the same quarter in 2023 [7][9]. Strategic Focus for 2025 - The company plans to expand franchise white-label partnerships to enhance its market presence [13]. - There is a focus on increasing pharmacy margins through supply chain optimization and strategic pricing [14]. - New wellness categories will be launched, including NAD+, testosterone replacement therapy, and peptide therapies [14]. - The onboarding of high-growth D2C healthcare companies on the VSDHOne platform will be accelerated [15]. - The company aims to attract and support more licensed nurses to enhance its provider network [15]. - Strategic tuck-in acquisitions of complementary D2C health brands are being pursued to improve product mix and margins [15]. Recognition and Milestones - Hydreight was ranked 9 on Deloitte's 2024 Technology Fast 50 list and 56 on the Technology Fast 500 list for North America [6][9]. - The company completed its first post-IPO financing, raising CAD 5.4 million in February 2025 to support its growth initiatives [6][9]. Operational Highlights - The company operates a network of over 3,000 nurses and 200+ physicians across all 50 states, facilitating a scalable telehealth and at-home care model [11][12]. - Hydreight's VSDHOne platform supports over 400 Direct to Consumer license holders, enabling rapid entry into the online healthcare space [11][21].